Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis

NCT02078882 ↗

Phase 4 Completed 16 enrolled Christopher Bowlus, MD Bristol-Myers Squibb · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if abatacept (Orencia) is effective in patients with primary biliary cirrhosis who do not respond adequately to standard treatment with ursodeoxycholic acid (UDCA, Urso, Ursodiol, Actigall).

Timeline

Start: 2014-09
Primary completion: 2018-10
Completion: 2018-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abatacept	Other / unclassified	125 mg	Subcutaneous

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis

Summary

Timeline

Drugs

Indications